Lorcaserin

BreastfeedingPediatric
  • TRADE NAME: Belviq (Eisai)
  • INDICATIONS: Obesity in adults who have at least one weight-related health condition, such as high blood pressure, Type II diabetes, or high cholesterol
  • CLASS: Serotonin receptor agonist
  • HALF-LIFE: ~11 hours

FDA APPROVAL DATE: 06/27/2012

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Antipsychotics, Bupropion, Dextromethorphan, Lithium, MAO inhibitors, SNRIs, SSRIs, St John's Wort, Tramadol, Tricyclic antidepressants, Triptans

PREGNANCY CATEGORY: X

On 2/13/2020, the U.S. Food and Drug Administration (FDA) requested that the manufacturer of lorcaserin (Belviq) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.

Our database has 36 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top